DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
| Status: | Completed |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/28/2017 |
| Start Date: | February 2010 |
| End Date: | June 23, 2014 |
Natural Killer Cell KIR and HLA Genotypes May Predict Response to Antibody Therapy in Follicular Lymphoma
This research trial studies deoxyribonucleic acid (DNA) analysis in predicting response to
antibody therapy in patients with follicular lymphoma treated on clinical trials Cancer and
Leukemia Group B (CALGB)-50402 or CALGB-50701. Studying samples of blood from patients with
follicular lymphoma in the laboratory may help doctors predict how well patients will
respond to treatment.
antibody therapy in patients with follicular lymphoma treated on clinical trials Cancer and
Leukemia Group B (CALGB)-50402 or CALGB-50701. Studying samples of blood from patients with
follicular lymphoma in the laboratory may help doctors predict how well patients will
respond to treatment.
PRIMARY OBJECTIVES:
l. To test the hypothesis that killer immunoglobulin-like receptor (KIR) and human leukocyte
antigen (HLA) genotypes predict overall response (partial response [PR], complete
response[CR], and unconfirmed complete response [CRu]) within 12 months to
rituximab-containing monoclonal antibody combinations in follicular lymphoma patients
treated on CALGB protocols 50402 and 50701.
SECONDARY OBJECTIVES:
I. To test the hypothesis that KIR and HLA genotypes are associated with survival outcomes
(progression-free survival [PFS] and overall survival [OS]) in follicular lymphoma patients
treated with rituximab-containing monoclonal antibody combinations on CALGB protocols 50402
and 50701.
OUTLINE:
Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping
and polymorphism analysis.
l. To test the hypothesis that killer immunoglobulin-like receptor (KIR) and human leukocyte
antigen (HLA) genotypes predict overall response (partial response [PR], complete
response[CR], and unconfirmed complete response [CRu]) within 12 months to
rituximab-containing monoclonal antibody combinations in follicular lymphoma patients
treated on CALGB protocols 50402 and 50701.
SECONDARY OBJECTIVES:
I. To test the hypothesis that KIR and HLA genotypes are associated with survival outcomes
(progression-free survival [PFS] and overall survival [OS]) in follicular lymphoma patients
treated with rituximab-containing monoclonal antibody combinations on CALGB protocols 50402
and 50701.
OUTLINE:
Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping
and polymorphism analysis.
Inclusion Criteria:
- Untreated follicular lymphoma
- Has received rituximab-containing monoclonal antibody therapy on CALGB-50402 or
CALGB-50701
- Patients have previously provided informed consent allowing correlative studies on
genomic DNA
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
